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Abstract: Prostatic acid phosphatase (PAP) is expressed in nociceptive neurons and functions as an ectonucleotidase. In-
jection of the secretory isoform of PAP has potent antinociceptive effects in mouse models of chronic pain. These data 
suggested that a small molecule activator of PAP may have utility as a novel therapeutic for chronic pain, while inhibitors 
could be used to acutely inhibit PAP in vitro and in vivo. To identify small molecule modulators of PAP activity, we vali-
dated a high throughput, fluorescence-based biochemical assay and then used this assay to screen a compound library. We 
decreased the frequency of false positive activators by subtracting compound fluorescence from the final assay fluores-
cence. This approach significantly reduced the number of false positive activators found in the screen. While no activators 
were confirmed, seven novel inhibitors of PAP were identified. Our results suggest this high throughput assay could be 
used to identify small molecule modulators of PAP activity.  
INTRODUCTION  
  Recently, we found that Prostatic Acid Phosphatase 
(PAP, also known as ACPP, EC 3.1.3.2) was expressed in 
nociceptive neurons and functioned as an ectonucleotidase, 
generating adenosine from adenosine monophosphate 
(AMP) [1, 2]. PAP knockout mice displayed enhanced noci-
ceptive responses in models of chronic inflammatory and 
neuropathic pain. Conversely, intrathecal injection of puri-
fied PAP protein had antinociceptive effects that lasted three 
days and were dependent on A1-adenosine receptor activa-
tion. These data suggested it might be possible to mimic the 
antinociceptive effects of PAP by identifying small-
molecules that allosterically activate PAP in nociceptive 
neurons. Currently, no small molecule activators of PAP 
exist.  
  In addition, there are no small molecules that selectively 
and potently inhibit PAP. While non-selective inhibitors like 
L-(+)-tartrate exist, these molecules inhibit other acid phos-
phatases [3]. The only other known PAP inhibitor, -
benzylaminobenzylphosphonic acid (BABPA), has a much 
lower IC50, in the nanomolar range [4, 5]. BABPA has not 
been extensively studied and may lack selectivity because it 
is a derivative of benzylphosphonic acid (BPA). BPAs were 
originally designed to inhibit protein tyrosine phosphatases 
(PTP), including those found in mitochondria [6], fibroblasts 
[7] and endothelial cells [8]. BPAs also inhibit PAP [5]. 
  The crystal structures of human and rat PAP are available 
[9-11] and could be used to rationally design inhibitors. 
However, a high throughput screen is needed to provide an  
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unbiased approach to identify allosteric activators and inhibi-
tors. Predicting a small molecule activator without knowing 
a potential docking site and mechanism would be very chal-
lenging. 
  A PAP activity assay using the fluorigenic substrate 
difluoro-4-methylumbelliferyl phosphate (DiFMUP) has been 
reported [12]. In this assay, the non-fluorescent DiFMUP is 
dephosphoylated by PAP converting it to 6,8-difluoro-4-
methylumbelliferone, a highly fluorescent molecule. In this 
report, we describe the validation of a high throughput ver-
sion of this PAP activity assay for the discovery of small 
molecule modulators of PAP activity. This assay was also 
used to screen a chemical library in search of activators and 
inhibitors of PAP. Small molecule activators of PAP may 
have use as research tools and/or serve as leads for novel 
antinociceptive therapeutic agents. Potent and selective in-
hibitors of PAP could be useful as research tools in exploring 
the biological function of PAP.  
MATERIALS AND METHODOLOGY  
Reagents  
  All common reagents such as HEPES, EDTA, fatty acid-
free bovine serum albumin (BSA), sodium L-(+)-tartrate, 
dimethyl formamide (DMF) and dimethyl sulfoxide (DMSO) 
were reagent-grade quality obtained from Thermo Fisher 
Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, 
MO). Purified human PAP (catalog # P1774) was obtained 
from Sigma-Aldrich. Difluoro-4-methylumbelliferyl phos-
phate (DiFMUP) was obtained from Invitrogen (cat # 
D22065). The solid black 384-well plates (cat# 3573) for the 
assay were from Corning Incorporated (Corning, NY). The 
Prestwick Chemical Library was obtained from Prestwick 
Chemical (Washington DC). The compounds for screening 
and IC50 determinations were obtained from the Asinex Cor-
poration (Moscow, Russia).  PAP HTS  Current Chemical Genomics, 2009, Volume 3    43 
PAP Assay 
  The PAP assay was performed by the addition of 0.5 μl 
of compound (or DMSO) to the well of a black 384-well 
plate followed by the addition of 25 μl of diluted PAP en-
zyme. After addition of enzyme, the compound fluorescence 
(background) was measured using a Victor V (Perkin Elmer) 
fluorescence plate reader. The fluorescence was measured 
using the 355 nm excitation filter and 460 nm emission filter 
(the ubelliferone filter set). Read time was 0.1 s/well. Fol-
lowing this “pre-read”, the reaction was initiated by addition 
of 25 μl of diluted DiFMUP substrate. DiFMUP stock solu-
tions were made in the solvent DMF. PAP and DiFMUP 
were diluted with assay buffer consisting of 50 mM HEPES 
pH 7.0, 1 mM EDTA, and 100 ug/ml fatty acid-free BSA. 
Following the initiation of the reaction with DiFMUP, the 
plates were incubated for one hour at 23ºC followed by the 
addition of 25 μl of a 180 mM sodium L-(+)-tartrate solution 
(in water) to stop the reaction. The PAP, DiFMUP, and stop 
solutions were delivered to the plate using the Multidrop
TM 
liquid handler (Thermo). The plate was then read in the Vic-
tor V plate reader as before. Specific fluorescence due to 
DiFMUP hydrolysis was obtained by subtracting the back-
ground relative fluorescence units (RFU) from the RFUs 
measured in the final plate read. These adjusted values were 
used for all percent inhibition/activation calculations, except 
where comparison data is shown. Error bars for data points 
represent standard deviations. Z’-factor values were derived 
by the published formula with Z’-factors of 0.5 – 1.0 indicat-
ing that an assay is robust for screening [13]. 
High Throughput Screen 
  For the high throughput screening of the Asinex chemical 
library, 0.5 μl of 1 mM compound in 100% DMSO was 
added to dry 384-well plates using a Biomek NX (Beckman 
Coulter Inc., Fullerton, CA), resulting in a final compound 
concentration of 10 μM for the primary screen. This dry 
spotting of compounds into assay plates was performed as a 
routine HTS method of conserving compound stock solu-
tions. This spotting method has been validated for transfer of 
0.5 μl DMSO with a CV of 6.3% and relative inaccuracy of -
2.0%. Final assay concentrations in the 50 μl enzyme reac-
tion were 5.5 mU/ml PAP (activity as defined by Sigma), 59 
μM DiFMUP, 10 M compound, 1% DMSO (from com-
pound), 0.6% DMF (from DiFMUP stock solution) and as-
say buffer. For the screening, each plate had 2x, max and 
min controls with DMSO spotted in the wells. Maximum 
(max) signal positive control wells contained only DMSO 
(no compound), while the minimum (min) signal control 
wells were obtained by adding assay buffer instead of PAP. 
L-(+)-tartrate would not dissolve in DMSO or water at a high 
enough concentration to generate the min controls. Since the 
RFUs obtained with high concentrations of L-(+)-tartrate 
were the same as wells without enzyme, we just added buffer 
without enzyme to create the min control wells. The 2x acti-
vation control wells received twice the concentration of 
PAP. The percent inhibition was calculated according to the 
following formula using background subtracted RFU data: 
% inhibition = 1 -
(compound RFU - min control RFU)
(max control RFU - min control RFU)
 100
 
  The absolute value of negative inhibition values denotes 
percent activation. The definition of a hit was a compound 
that displayed 50% inhibition in the primary screen or 50% 
activation (-50% inhibition) with the 2x control being 100% 
activation (-100% inhibition). IC50 value was defined as the 
concentration of inhibitor calculated to inhibit 50 % of the 
assay signal based on a serial dilution of compound. Values 
were calculated using either a four or three-parameter dose 
response (variable slope) equation in Graphpad Prism or 
ActivityBase (IDBS, Alameda, CA). For the IC50 determina-
tions, serial dilutions of compounds were performed in 100% 
DMSO with a two-fold dilution scheme resulting in 10 con-
centrations of compound starting at a high concentration of 
20  μM compound in the final assay. For the HTS assay, 
these compound dilutions were spotted onto plates and the 
assay performed at 1% DMSO final concentration as de-
scribed for the primary screen.  
RESULTS 
  PAP activity can readily be measured using the substrate 
DiFMUP (12 and EnzChek
TM Acid Phosphatase Assay Kit, 
Invitrogen). This substrate has the advantage over the older 
4-methylumbelliferone phosphate in that it provides sensi-
tive detection of PAP activity at acidic as well as neutral pH 
[12]. We used this substrate to detect PAP activity in an end 
point assay which is amenable for high throughput screen-
ing. Enzyme assays were performed at pH 7.0 to more 
closely mimic extracellular pH where the active site of PAP 
is localized. The assay was developed with a final volume of 
50 l using the 384-well plate format to match the intended 
screening format. The general assay set-up included the addi-
tion of diluted PAP to the well followed by the addition of 
DiFMUP to initiate the reaction. The reaction was termi-
nated with sodium L-(+)-tartrate and the fluorescence deter-
mined in a plate reader. PAP and DiFMUP were both di-
luted with assay buffer (50 mM HEPES pH 7.0, 1 mM 
EDTA, 100 ug/ml BSA). The Km for DiFMUP was experi-
mentally determined to be 918 μM (data not shown). The 
final concentration of DiFMUP was 59 μM and therefore the 
assay should be sensitive to substrate competitive com-
pounds.  
  The activity in the assay was directly proportional to the 
concentration of PAP, up to at least 22 mU/ml (Fig. 1). We 
 
 
 
 
 
 
 
 
Fig. (1). PAP enzyme titration. PAP was titrated into the assay 
under final assay conditions with an incubation time of one hour in 
the presence of 1% DMSO. Data points represent the average of 
two determinations per concentration and error bars represent stan-
dard deviations. Data are representative of three independent ex-
periments.  44    Current Chemical Genomics, 2009, Volume 3  Larsen et al. 
chose to use 5.5 mU/ml as the final concentration in the 
assay to provide a robust assay window. 
  The chosen concentration of enzyme resulted in a linear 
time course using this assay for at least 90 minutes under 
final assay conditions in the presence of 1% DMSO (Fig. 2). 
The enzyme titration and time course data suggested that the 
assay conditions should be sensitive to compounds that are 
either inhibitors and activators of PAP activity.  
 
 
 
 
 
 
 
 
 
Fig. (2). PAP assay time course. A time course study was per-
formed under final assay conditions in the presence of 1% DMSO. 
Data points represent the average of two determinations per time 
point and error bars represent standard deviations. Data are repre-
sentative of three independent experiments.  
 
  Since the compounds to be screened were dissolved in 
DMSO, the tolerance for DMSO was examined at various 
DMSO concentrations (Fig. 3). The assay was shown to be 
tolerant to DMSO concentrations up to at least 2.5%. In the 
final screening assay, the maximal concentration that the 
enzyme is exposed to is 2% DMSO before the addition of 
substrate. 
 
 
 
 
 
 
 
 
 
Fig. (3). DMSO tolerance of PAP assay. The indicated concentra-
tions of DMSO were tested in the PAP assay. Data points represent 
the average of three determinations per concentration and error bars 
represent standard deviations. Data are representative of three inde-
pendent experiments.  
 
  The variability of the assay was characterized in a 384-
well plate format. The HTS version of the assay employed 
work station level automated liquid handling system using 
the Biomek NX for delivery of compound or DMSO (0.5 l) 
to the plate followed by addition of PAP (25 μl), DiFMUP 
(25 μl) and L-(+)-tartrate stop solution (25 μl), in that order, 
using the Multidrop
TM (Thermo). IC50 values for sodium L-
(+)-tartrate were determined using the HTS protocol, includ-
ing use of the liquid handler (Fig. 4). The IC50 values ob-
tained were 53 and 40 μM for two separate determinations. 
These values are in close agreement with the published IC50 
value of 29 μM [14]. The Hill slopes were 0.96 and 0.89, 
very close to the expected value of 1.0 for inhibition of a 
single enzyme. Thus, reproducible IC50 values can be ob-
tained using the automated version of the PAP assay.  
 
 
 
 
 
 
 
 
 
Fig. (4). L-(+)-tartrate IC50 value determination using the auto-
mated PAP assay. Data points represent the average of five deter-
minations per concentration and error bars represent standard devia-
tions. Data are representative of two independent experiments.  
 
  To assess single-point variability of the assay with full 
automation, all wells of a 384-well plate were pre-spotted 
with 0.5 μl of DMSO (Fig. 5). The pre-spotted DMSO 
plates simulated compound plates that were to be screened. 
The desired screen was one that could detect both activators 
and inhibitors of PAP. Therefore, two plates for each condi-
tion were used to determine the maximum (max) signal, 
minimum (min) signal and a 2x enzyme concentration to 
mimic 2x activation of enzymatic activity. The variability for 
inhibition was determined using the max and min plates 
while the activation window was determined based on the 
max and 2x plates. The %CV of the max and 2x plates were 
5.4 and 4.4%, respectively, while the %CV for the min plates 
was 11.8%. The Z’-factor for the inhibition assay window 
was 0.83 and for the activation assay window it was 0.60. 
Thus, the assay was highly robust with good variability ame-
nable for high throughput screening for both activators and 
inhibitors of PAP activity.  
 
 
 
 
 
 
 
 
 
Fig. (5). PAP assay variability assessment. All wells of a 384-well 
plate were pre-spotted with 0.5 l of DMSO. Two plates each were 
used to determine the maximum signal (middle), minimum signal 
(bottom), and a 2x enzyme concentration (top). The Z’-factors for 
the inhibition assay window (max/min) and the activation assay 
window (max/2x) are shown.  PAP HTS  Current Chemical Genomics, 2009, Volume 3    45 
  As part of assay validation, a small collection of 1,120 
compounds purchased from the Prestwick Chemical com-
pany was screened to assess the performance of the assay in 
the presence of diverse compounds using the HTS protocol. 
On initial testing of this library, several compounds appeared 
to be activators based on the controls, but their authenticity 
was suspect due to their high RFU values. The contribution 
of compound fluorescence to the final measured fluorescence 
at the end of the assay was determined by reading fluores-
cence before addition of DiFMUP and comparing the RFUs 
obtained at the end of the assay (data not shown and Fig. 6). 
This analysis suggested that compound fluorescence interfer-
ence could be reduced by subtracting “pre-read” values from 
final fluorescence values. Therefore, we modified the assay 
protocol to include determining the fluorescence due to the 
compound by reading the fluorescence of the wells before 
addition of DiFMUP. This value was subtracted from the 
final read value before determining activity based on the con-
trols (which were also background subtracted this way). The 
Prestwick collection of compounds was screened at 10 μM 
compound concentration and the data analyzed with and 
without the background subtraction adjustment to the per-
cent inhibition data (Fig. 6). Negative percent inhibition 
values indicate activation e.g. a -100% value represents a 
100% increase in RFU value or two-fold higher activity than 
max control. For this assay, the inhibitor and activator cut-
offs were defined as 50% and -50% calculated inhibition val-
ues, respectively. Without background subtraction, there 
were 10 apparent activators with % inhibition values ranging 
from -50 to -428%.  
  After background subtraction was applied to the data, 
there was only one activator identified. This compound gen-
erated the highest activation, 428% without background sub-
traction, and after subtraction was reduced to 63% activation. 
This compound had very high fluorescence and was deemed 
a false positive. This molecule was triamterene, a drug 
known to be highly fluorescent using the wavelengths em-
ployed for this assay [15]. This data demonstrated that the 
background subtraction method reduced the number of false 
positive activators by ten-fold, though compounds with very 
high fluorescence can still appear as an activator. It should 
be noted that there was a modest inhibitor (61%) whose % 
inhibition value was unchanged by the background subtrac-
tion. Therefore, we changed the HTS protocol to include this 
background read and subtraction method to reduce the num-
ber of false positive activators. The Z’-factors of the controls 
for each of the four plates were all 0.78 for both the inhibi-
tion and the activation assay windows.  
  A diverse collection of 28,800 small organic molecules 
purchased from Asinex Corporation were screened for PAP 
activation or inhibition (Fig. 7). In a retrospective study, the 
data was analyzed without and with background subtraction. 
Without background subtraction, there were 166 apparent 
activators compared to 36 using background subtraction. 
Hence, the background subtraction method resulted in a 
nearly 5-fold reduction in false positive activators. In addi-
tion to these initial activators, 18 inhibitors were identified 
during the screen. Thus, the active rates were 0.06% and 
0.13% for inhibition and activation, respectively. The plate 
Z’-factors for the screen were all >0.70 for the inhibition 
window and >0.50 for the activation window.  
  The activators were triaged by manual inspection of the 
raw fluorescence data. After this manual inspection, 26 acti-
vators that had pre-read values of >1,000-fold above controls 
were eliminated and 10 activators were re-tested in IC50 
format where none of them confirmed activity. Consistent 
with the lack of confirmation, all but two of these activators 
had pre-read fluorescence values above control wells.  
  In contrast to the activator hits, 7 of the 18 inhibitor hits 
confirmed activity in IC50 determinations, ranging from 2.0 
to 19 M (Table 1). The concentration response data used to 
calculate IC50 values for hit compounds 1 and 2 are provided 
as representative curves (Fig. 8). Examination of the struc-
tures of these inhibitors indicated that three of them (com-
pounds 2, 3, and 5) have the same core scaffold consisting of 
6-hydroxy-5-nitropyrimidin-4(3H)-one. Compounds 4 and 6 
are both carboxylic acids. Compound 1, with a 2 μM IC50 
value, was over 20-fold more potent than the L-(+)-tartrate 
control compound. Thus, this PAP assay was successful in 
finding inhibitors of PAP activity. 
DISCUSSION 
  PAP has been intensively studied for 70 years in the 
prostate cancer field. Recent work has found that PAP func-
tions as an ectonucleotidase in nociceptive neurons [2]. In-
traspinal injections of PAP produces antinociceptive, anti-
hyperalgesic and antiallodynic effects that last longer than 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Screen of the Prestwick collection with the PAP assay. 
Each point represents a compound. The percent inhibition values 
were calculated without (A) and with (B) background subtraction.  46    Current Chemical Genomics, 2009, Volume 3  Larsen et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). High throughput screening of a chemical library. The same single point screening data is shown in scattergrams without background 
subtraction (A) and with background subtraction (B) showing percent inhibition for each compound tested. Activation values result in nega-
tive percent inhibition values. 
 
Table 1.  Activities of Confirmed Inhibitors from Chemical Library using PAP Assay 
Compound Asinex  Identifier
a Structure  IC50 (M)
b 
1 BAS  07119722 
N
O
O
O
Cl  
2.0 
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(Table 1). Contd….. 
Compound Asinex  Identifier
a Structure  IC50 (M)
b 
2 BAS  08865249 
O
H
N
N
O
OH
N+ O
O-
 
6.7 
3 BAS  08863852 
O
H
N
N
O
OH
N+ O
O-
 
6.9 
4 BAS  03013122  N
HN
N N
OH
O
 
8.0 
5 BAS  08862870  H
N
N
O
OH
N+ O
O-
O
 
13.8 
6 BAS  02830262 
S
O
O
Br O
HO
O
 
15.4 
7 BAS  00669251 
N
N
S N I
 
19.3 
aChemical identifier number provided by Asinex Corporation. 
bFor IC50 determinations, serial dilutions of compounds were tested starting at a high concentration of 20 M.  48    Current Chemical Genomics, 2009, Volume 3  Larsen et al. 
morphine in mouse models of chronic pain, including 
chronic inflammatory and neuropathic pain. These antinoci-
ceptive effects are due to dephosphorylation of extracellular 
AMP by PAP to produce adenosine which subsequently ac-
tivates A1-adenosine receptors on nociceptive neurons and in 
the spinal cord. These data have led to the hypothesis that 
small molecules that enhance endogenous PAP activity may 
have potential therapeutic value in treating chronic pain con-
ditions. In addition, potent and selective inhibitors could be 
useful research tools for in vivo and in vitro experiments.  
  In this report, we have validated a PAP high throughput 
assay to identify inhibitors and activators of PAP activity 
and used it to screen a diverse library of 28,800 small mole-
cules. The assay signal was shown to increase in a linear 
fashion with enzyme concentration and time. The assay was 
also tolerant up to at least 2.5% DMSO. As part of the vali-
dation, the control inhibitor sodium L-(+)-tartrate was used 
to determine IC50 values using the final HTS assay with 
automation. The IC50 values obtained were consistent be-
tween experiments, with the individual values within 15% of 
the mean. Whole 384-well plate variability studies using pre-
spotted DMSO plates and automation were done to assess 
the variability in detection of both inhibitors and activators 
with the same assay. The results generated Z’-factors of 0.60 
for the activation assay window and 0.83 for the inhibition 
assay window, indicating a robust assay for detection of both 
types of hits.  
  As is typical for HTS validation, we screened a small set 
of compounds (the Prestwick collection) using high through-
put methodology, to assess the performance of the assay in 
the presence of diverse compounds. These set of four plates 
resulted in Z’-factors of 0.78 for both the activation and 
inhibition window. In initial data analysis, it was apparent 
that a number of fluorescent compounds were affecting the 
signal and appearing as activators. Therefore, we tested the 
effect of subtracting compound fluorescence (background) 
for each compound. Compound fluorescence was estimated 
by reading the assay plate before the addition of substrate. 
There was a volume difference between reads where the 
compound was in 25 μl in the pre-read and 75 μl for the final 
read. Although the concentration of compound is three-fold 
higher in the pre-read, there is three-fold more volume of 
compound detected by the plate reader in the final read. 
Thus, it may be expected that the volume difference, by it-
self, may not preclude this type of background subtraction. 
In practice, the background fluorescence subtraction method 
usually reduced the net signal obtained from fluorescent 
compounds to similar values as the max controls (no activ-
ity). This is evident in large scale in the comparison of the 
Prestwick screening with and without background subtrac-
tion where the number of apparent activator hits was reduced 
from 10 to 1 using background subtraction. At even larger 
scale, the screening of 28,800 compounds, compound fluo-
rescence subtraction led to the reduction of apparent activa-
tors from 166 to 36. The pre-read data also allowed manual 
triage of the 36 down to 10 by eliminating those that had 
extraordinarily high pre-read fluorescence.  
  It is also apparent from our data that this subtraction 
method is not 100% reliable. In both the Prestwick set 
screening and the full scale HTS, clearly fluorescent com-
pounds still appeared as activators. For instance, in the 
Prestwick set, a known fluorescent diuretic drug, triam-
terene, was still not “subtracted-out” completely as an activa-
tor. The inner filter effect observed for many fluorophores at 
high concentration is a well known phenomenon. The inner 
filter effect occurs when a fluorophore self-absorbs some of 
the emitted light resulting in signal non-linearity with 
fluorophore concentration. This only occurs at a significant 
degree at high (micromolar) concentrations. We speculate 
that compounds like triamterene self-quench at high concen-
tration, as occurs in the pre-read where the compound con-
centration is 20 M. When the compound is diluted, as in the 
final read, total compound fluorescence will be higher due to 
reduced self-quenching. This explanation is also feasible for 
the lack of confirmation of apparent activator hits from the 
screen since almost all of them (8 out of 10) had significant 
pre-read fluorescence.  
  In sum, the background fluorescence subtraction method 
for the PAP assay significantly reduced the false positive 
activators, but did not eliminate them. The advantage of this 
method over just eliminating all fluorescent compounds is 
that genuine activators that happen to also be weakly fluo-
rescent would not be lost. Also, the complete elimination of 
fluorescent compounds requires one to establish a cut-off for 
what is fluorescent and what is not considered fluorescent. 
Kinetic assays are another method for eliminating fluores-
cence interference by establishing a background in the first 
read and measuring the change in fluorescence. However, 
highly fluorescent compounds are still problematic for ki-
netic assays since velocity will be less reliable due to high 
background. In addition, kinetic assays are typically not as 
high throughput as end point assays, which is why we chose 
an end point format. Also, not all high throughput assays can 
be readily converted to kinetic assays due to slow kinetics or 
a requirement for a development step in order to generate 
signal. 
  In contrast to the activator results, seven novel inhibitors 
of PAP were identified. The most potent inhibitor had an 
IC50 of 2 μM. Thus, this compound is over 20-fold more 
potent than the classically used L-(+)-tartrate. Three of the 
actives had the same core scaffold. Five of the seven com-
pounds had negatively-charged nitro or carboxylic acid 
groups. It is tempting to speculate that these groups may 
function as phosphate mimetics in inhibiting the active site 
 
 
 
 
 
 
 
 
 
Fig. (8). IC50 value determination for compounds 1 and 2. Com-
pounds were serially diluted in 100% DMSO then transferred to 
assay plates for the PAP activity assay. Concentration response 
curves are shown for compounds 1 () and 2 (). PAP HTS  Current Chemical Genomics, 2009, Volume 3    49 
of PAP. The specificity of these PAP inhibitors is under in-
vestigation.  
CONCLUSIONS  
  We have validated a high throughput assay for the dis-
covery of small molecule modulators of PAP activity. Whole 
plate and IC50 variability studies confirmed the robustness of 
this assay for high throughput screening. Subtraction of 
compound fluorescence from the total fluorescence of each 
reaction was a useful technique to reduce, but not eliminate, 
false positive activator hits due to compound fluorescence 
contribution to signal. A chemical library was screened re-
sulting in no confirmed activators, but 7 confirmed inhibi-
tors. The most potent inhibitor had an IC50 of 2 μM which is 
20-fold more potent than the known inhibitor L-(+)-tartrate. 
These compounds may be useful as starting points in the 
development of a chemical probe for PAP. Taken together, 
the PAP assay described herein is amenable for the discov-
ery of activators and inhibitors of PAP. 
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